Directorate Change
Renalytix plc announced that Non-Executive Chair Julian Baines MBE intends to step down on December 31, 2026, following the company's recent £10.5 million gross proceeds fundraising and a multi-year partnership with Quest Diagnostics. The company is actively interviewing candidates for the Chairman position to support the strategic partnering and distribution of its kidney disease diagnostic product, kidneyintelX.dkd. This leadership transition occurs as Renalytix focuses on the widespread adoption of its technology, which has received FDA authorization and Medicare reimbursement.
Select text to share a quote on X · sign in to keep highlights & notes in your RENX notes
Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focussed on kidney disease, announces that Julian Baines MBE has indicated his intention to stand down as Non-Executive Chair of Renalytix on 31 December 2026. Julian re-joined the Board of Renalytix in November 2024, having been Non-Executive Chairman from March 2018 to June 2020.
The Company is currently interviewing several senior industry executives who can support both US and global strategic partnering and distribution strategy for Renalytix’s lead product kidneyintelX.dkd and follow-on programmes. The Company expects to present candidate recommendations to the board of directors in the short-term for approval and will provide shareholders with further updates in due course.
Commenting Julian Baines, MBE, commented:
“With the recent signing of our multi-year partnership with Quest Diagnostics and the successful fundraising, which provides £10.5 million in gross proceeds for the Company, I feel it is an appropriate time for me to stand down, now that Renalytix’s funding and pathway to wide-scale adoption is on track.
“I firmly believe that kidneyintelX.dkd will revolutionise the way clinicians manage kidney disease and deliver improved patient outcomes. The Quest collaboration gives us the opportunity to rapidly rollout kidneyintelX.dkd testing services across the United States. I am very proud to have been part of Renalytix for the last two years as the business stabilised and we took actions to preserve capital and execute our cash plans.”
James McCullough, Chief Executive Officer, commented:
“I would like to extend the full thanks of the Board, all Renalytix staff and shareholders for Julian’s support over the many years since our London flotation in November 2018. Since then, Renalytix has published major data publications, and delivered regulatory, reimbursement and commercial milestones. Julian has been a valued part of our strategic decisions and success. I am delighted by the quality of the candidates with whom we are already engaging for the Chairman position and expect a smooth transition.”
About kidneyintelX.dkd and RenalytixTM (www.kidneyintelx.com and www.renalytix.com)
RenalytixTM (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company dedicated to optimizing kidney disease management through precision-based care intervention. It’s KidneyIntelX™ technology and data-driven insights help clinical teams understand patient level of risk for progressive decline in kidney function in the earliest stages of diabetic kidney disease. This enables clinicians to focus resources and guideline-recommended treatment, providing the best chance for improving kidney and overall renal-cardio-metabolic outcomes.
RenalytixTM has been granted FDA authorization and Medicare reimbursement for kidneyintelX.dkd which is offered commercially throughout the United States. For more information about the kidneyintelX.dkd test, visit www.kidneyintelx.com.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.